Immune Thrombocytopenia (ITP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Immune Thrombocytopenia (ITP) Marketed and Pipeline Drugs Market Report Overview
Immune Thrombocytopenia (ITP) is an autoimmune syndrome involving the antibody- and cell-mediated destruction of platelets and suppression of platelet production. This increases an affected individual’s susceptibility to bleeding. More specifically, the destruction and suppression of platelets are due to B cell (and sometimes CD8+ T cell) autoimmune reactions directed against circulating platelets and megakaryocytes.
The Immune Thrombocytopenia marketed and pipeline drugs market includes an assessment of the disease epidemiology, leading marketed products with sales forecast, pricing and reimbursement, late-to-mid-stage pipeline products with phase transition success rate (PTSR), and likelihood of approval (LoA) in immune thrombocytopenia (ITP).
Immune Thrombocytopenia Marketed Drugs Segmentation by Mechanisms of Action
The key mechanisms of action for ITP marketed drugs are receptor agonist, enzyme inhibitor, protein and peptide inhibitor, cells and cell organelle inhibitor, genes, nucleic acids & related components inhibitor, cytotoxic to cell, and receptor antagonist. Most of the marketed drugs for ITP are receptor agonists, enzyme inhibitors, and protein and peptide inhibitors.
ITP Marketed Drugs Analysis, by Mechanisms of Action, 2023 (%)
For more MoA insights into the ITP marketed drugs market, download a free report sample
Immune Thrombocytopenia Marketed Drugs Segmentation by Molecule Type
The key molecule types for ITP marketed drugs are small molecule and biologic. The pipeline market is dominated by small molecule.
ITP Marketed Drugs Analysis, by Molecule Type, 2023 (%)
For more molecule type insights into the ITP marketed drugs market, download a free report sample
Immune Thrombocytopenia Marketed Drugs Segmentation by Routes of Administration
The key routes of administration for ITP marketed drugs are oral, injection, topical, suppository, and inhalational. Majority of the drugs are administered through the oral route.
Immune Thrombocytopenia Marketed Drugs Analysis, by Routes of Administration, 2023 (%)
For more routes of administration insights into the ITP marketed drugs market, download a free report sample
Immune Thrombocytopenia Pipeline Drugs Segmentation by Mechanisms of Action
The key mechanisms of action for ITP pipeline drugs are receptor agonist, enzyme inhibitor, receptor antagonist, cytotoxic to cell, protein and peptide inhibitor, enzyme replacement, and biological factor inhibitor. Most of the ITP pipeline drugs are receptor agonists and enzyme inhibitors.
Immune Thrombocytopenia Pipeline Drugs Analysis, by Mechanisms of Action, 2023 (%)
For more MoA insights into the ITP pipeline drugs market, download a free report sample
Immune Thrombocytopenia Pipeline Drugs Segmentation by Routes of Administration
The key routes of administration for ITP pipeline drugs are oral and injection. Of all the ITP pipeline drugs, injection is the most common route of administration.
ITP Pipeline Drugs Analysis, by Routes of Administration, 2023 (%)
For more RoA insights into the ITP pipeline drugs market, download a free report sample
Immune Thrombocytopenia Pipeline Drugs Segmentation by Molecule Type
The key molecule types for ITP pipeline drugs are small molecule and biologic. Majority of the ITP pipeline drugs are accounted for by biologic.
ITP Pipeline Drugs Analysis, by Molecule Types, 2023 (%)
For more molecule type insights into the ITP pipeline drugs market, download a free report sample
Top Sponsors in the Immune Thrombocytopenia Marketed and Pipeline Drugs Market
Some of the top sponsors in the ITP marketed and pipeline drugs market are Peking University People’s Hospital, Shandong University, Novartis AG, Argenx SE, Jiangsu Hengrui Medicine Co Ltd, UCB SA, Sanofi, 3SBio Inc, Principia Biopharma Inc, and Intas Pharmaceuticals Ltd.
Immune Thrombocytopenia Marketed Drugs Market Report Overview
| Key Mechanisms of Action | Receptor Agonist, Enzyme Inhibitor, Protein and Peptide Inhibitor, Cells and Cell Organelle Inhibitor, Genes, Nucleic Acids & Related Components Inhibitor, Cytotoxic To Cell, and Receptor Antagonist |
| Key Molecule Types | Small Molecule and Biologic |
| Key Routes of Administration | Oral, Injection, Topical, Suppository, and Inhalational |
Immune Thrombocytopenia Pipeline Drugs Market Report Overview
| Key Mechanisms of Action | Receptor Agonist, Enzyme Inhibitor, Receptor Antagonist, Cytotoxic to Cell, Protein and Peptide Inhibitor, Enzyme Replacement, and Biological Factor Inhibitor |
| Key Routes of Administration | Oral and Injection |
| Key Molecule Types | Small Molecule and Biologic |
| Top Sponsors (Marketed and Pipeline Drugs) | Peking University People’s Hospital, Shandong University, Novartis AG, Argenx SE, Jiangsu Hengrui Medicine Co Ltd, UCB SA, Sanofi, 3SBio Inc, Principia Biopharma Inc, and Intas Pharmaceuticals Ltd |
Segments Covered in the Report
Immune Thrombocytopenia Marketed Drugs Market Mechanisms of Action Outlook (Number of Products)
- Receptor Agonist
- Enzyme Inhibitor
- Protein and Peptide Inhibitor
- Cells and Cell Organelle Inhibitor
- Genes, Nucleic Acids & Related Components Inhibitor
- Cytotoxic To Cell
- Receptor Antagonist
Immune Thrombocytopenia Marketed Drugs Market Molecule Types Outlook (Number of Products)
- Small Molecule
- Biologic
Immune Thrombocytopenia Marketed Drugs Market Routes of Administration Outlook (Number of Products)
- Oral
- Injection
Immune Thrombocytopenia Pipeline Drugs Market Mechanisms of Action Outlook (Number of Products)
- Receptor Agonist
- Enzyme Inhibitor
- Receptor Antagonist
- Cytotoxic to Cell
- Protein and Peptide Inhibitor
- Enzyme Replacement
- Biological Factor Inhibitor
Immune Thrombocytopenia Pipeline Drugs Market Routes of Administration Outlook (Number of Products)
- Oral
- Injection
Immune Thrombocytopenia Pipeline Drugs Market Molecule Types Outlook (Number of Products)
- Small Molecule
- Biologic
Scope
GlobalData’s Immune Thrombocytopenia (ITP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Retail or Manufacturer Price of Products
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the ITP market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ITP market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently Asked Questions
The key mechanisms of action in the ITP pipeline drugs market are receptor agonist, enzyme inhibitor, receptor antagonist, cytotoxic to cell, protein and peptide inhibitor, enzyme replacement, and biological factor inhibitor.
The key routes of administration in the ITP pipeline drugs market are oral and injection.
The key molecule types in the ITP pipeline drugs market are small molecule and biologic.
Some of the top sponsors for the ITP marketed and pipeline drugs market are Peking University People’s Hospital, Shandong University, Novartis AG, Argenx SE, Jiangsu Hengrui Medicine Co Ltd, UCB SA, Sanofi, 3SBio Inc, Principia Biopharma Inc, and Intas Pharmaceuticals Ltd.
Get in touch to find out about our multi-purchase discounts
reportstore@globaldata.com
Tel +44 (0) 20 7947 2960
Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.
Testimonial
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Related reports
View more Thrombocytopenia reports